CD8A and neoplasm: The administration of L19-IL2 in combination with FOLFOX or as single agent had a potent effect on recruitment and activation of both CD8a+ T-lymphocytes and NK into the tumor front (Fig. 6c and d; Supplementary Fig. 8b-d), while those cells where not present in both CTR and FOLFOX treated tumors.